Targeted nanogel conjugate for improved stability and cellular permeability of curcumin

Synthesis, pharmacokinetics, and tumor growth inhibition

Xin Wei, Thulani H. Senanayake, Anna Bohling, Serguei V Vinogradov

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Curcumin (CUR) is a unique natural compound with promising anticancer and anti-inflammatory activities. However, the therapeutic efficacy of curcumin was challenged in clinical trials, mostly due to its low bioavailability, rapid metabolism, and elimination. We designed a nanodrug form of curcumin, which makes it stable and substantially enhances cellular permeability and anticancer activity at standard oral administration. Curcumin was conjugated as an ester to cholesteryl-hyaluronic acid (CHA) nanogel that is capable of targeted delivery to CD44-expressing drug-resistant cancer cells. CHA-CUR nanogels demonstrated excellent solubility and sustained drug release in physiological conditions. It induced apoptosis in cancer cells, suppressing the expression of NF-κB, TNF-α, and COX-2 cellular targets similar to free curcumin. Pharmacokinetic/pharmacodynamic (PK/PD) studies also revealed improved circulation parameters of CHA-CUR at oral, i.p. and i.v. administration routes. CHA-CUR showed targeted tumor accumulation and effective tumor growth inhibition in human pancreatic adenocarcinoma MiaPaCa-2 and aggressive orthotropic murine mammary carcinoma 4T1 animal models. CHA-CUR treatment was well-tolerated and resulted in up to 13-fold tumor suppression, making this nanodrug a potential candidate for cancer prevention and therapeutic treatment.

Original languageEnglish (US)
Pages (from-to)3112-3122
Number of pages11
JournalMolecular Pharmaceutics
Volume11
Issue number9
DOIs
StatePublished - Sep 2 2014

Fingerprint

Curcumin
Permeability
Pharmacokinetics
Hyaluronic Acid
Growth
Neoplasms
NanoGel
Cholesterol Esters
Therapeutics
Solubility
Biological Availability
Oral Administration
Adenocarcinoma
Anti-Inflammatory Agents
Animal Models
Clinical Trials
Apoptosis
Breast Neoplasms

Keywords

  • Curcumin
  • NF-κB inhibition
  • PK/PD parameters
  • animal cancer models
  • nanogel-drug conjugate

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery
  • Medicine(all)

Cite this

Targeted nanogel conjugate for improved stability and cellular permeability of curcumin : Synthesis, pharmacokinetics, and tumor growth inhibition. / Wei, Xin; Senanayake, Thulani H.; Bohling, Anna; Vinogradov, Serguei V.

In: Molecular Pharmaceutics, Vol. 11, No. 9, 02.09.2014, p. 3112-3122.

Research output: Contribution to journalArticle

Wei, Xin ; Senanayake, Thulani H. ; Bohling, Anna ; Vinogradov, Serguei V. / Targeted nanogel conjugate for improved stability and cellular permeability of curcumin : Synthesis, pharmacokinetics, and tumor growth inhibition. In: Molecular Pharmaceutics. 2014 ; Vol. 11, No. 9. pp. 3112-3122.
@article{08e34eac6fdb49279cf6dca964caf5af,
title = "Targeted nanogel conjugate for improved stability and cellular permeability of curcumin: Synthesis, pharmacokinetics, and tumor growth inhibition",
abstract = "Curcumin (CUR) is a unique natural compound with promising anticancer and anti-inflammatory activities. However, the therapeutic efficacy of curcumin was challenged in clinical trials, mostly due to its low bioavailability, rapid metabolism, and elimination. We designed a nanodrug form of curcumin, which makes it stable and substantially enhances cellular permeability and anticancer activity at standard oral administration. Curcumin was conjugated as an ester to cholesteryl-hyaluronic acid (CHA) nanogel that is capable of targeted delivery to CD44-expressing drug-resistant cancer cells. CHA-CUR nanogels demonstrated excellent solubility and sustained drug release in physiological conditions. It induced apoptosis in cancer cells, suppressing the expression of NF-κB, TNF-α, and COX-2 cellular targets similar to free curcumin. Pharmacokinetic/pharmacodynamic (PK/PD) studies also revealed improved circulation parameters of CHA-CUR at oral, i.p. and i.v. administration routes. CHA-CUR showed targeted tumor accumulation and effective tumor growth inhibition in human pancreatic adenocarcinoma MiaPaCa-2 and aggressive orthotropic murine mammary carcinoma 4T1 animal models. CHA-CUR treatment was well-tolerated and resulted in up to 13-fold tumor suppression, making this nanodrug a potential candidate for cancer prevention and therapeutic treatment.",
keywords = "Curcumin, NF-κB inhibition, PK/PD parameters, animal cancer models, nanogel-drug conjugate",
author = "Xin Wei and Senanayake, {Thulani H.} and Anna Bohling and Vinogradov, {Serguei V}",
year = "2014",
month = "9",
day = "2",
doi = "10.1021/mp500290f",
language = "English (US)",
volume = "11",
pages = "3112--3122",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Targeted nanogel conjugate for improved stability and cellular permeability of curcumin

T2 - Synthesis, pharmacokinetics, and tumor growth inhibition

AU - Wei, Xin

AU - Senanayake, Thulani H.

AU - Bohling, Anna

AU - Vinogradov, Serguei V

PY - 2014/9/2

Y1 - 2014/9/2

N2 - Curcumin (CUR) is a unique natural compound with promising anticancer and anti-inflammatory activities. However, the therapeutic efficacy of curcumin was challenged in clinical trials, mostly due to its low bioavailability, rapid metabolism, and elimination. We designed a nanodrug form of curcumin, which makes it stable and substantially enhances cellular permeability and anticancer activity at standard oral administration. Curcumin was conjugated as an ester to cholesteryl-hyaluronic acid (CHA) nanogel that is capable of targeted delivery to CD44-expressing drug-resistant cancer cells. CHA-CUR nanogels demonstrated excellent solubility and sustained drug release in physiological conditions. It induced apoptosis in cancer cells, suppressing the expression of NF-κB, TNF-α, and COX-2 cellular targets similar to free curcumin. Pharmacokinetic/pharmacodynamic (PK/PD) studies also revealed improved circulation parameters of CHA-CUR at oral, i.p. and i.v. administration routes. CHA-CUR showed targeted tumor accumulation and effective tumor growth inhibition in human pancreatic adenocarcinoma MiaPaCa-2 and aggressive orthotropic murine mammary carcinoma 4T1 animal models. CHA-CUR treatment was well-tolerated and resulted in up to 13-fold tumor suppression, making this nanodrug a potential candidate for cancer prevention and therapeutic treatment.

AB - Curcumin (CUR) is a unique natural compound with promising anticancer and anti-inflammatory activities. However, the therapeutic efficacy of curcumin was challenged in clinical trials, mostly due to its low bioavailability, rapid metabolism, and elimination. We designed a nanodrug form of curcumin, which makes it stable and substantially enhances cellular permeability and anticancer activity at standard oral administration. Curcumin was conjugated as an ester to cholesteryl-hyaluronic acid (CHA) nanogel that is capable of targeted delivery to CD44-expressing drug-resistant cancer cells. CHA-CUR nanogels demonstrated excellent solubility and sustained drug release in physiological conditions. It induced apoptosis in cancer cells, suppressing the expression of NF-κB, TNF-α, and COX-2 cellular targets similar to free curcumin. Pharmacokinetic/pharmacodynamic (PK/PD) studies also revealed improved circulation parameters of CHA-CUR at oral, i.p. and i.v. administration routes. CHA-CUR showed targeted tumor accumulation and effective tumor growth inhibition in human pancreatic adenocarcinoma MiaPaCa-2 and aggressive orthotropic murine mammary carcinoma 4T1 animal models. CHA-CUR treatment was well-tolerated and resulted in up to 13-fold tumor suppression, making this nanodrug a potential candidate for cancer prevention and therapeutic treatment.

KW - Curcumin

KW - NF-κB inhibition

KW - PK/PD parameters

KW - animal cancer models

KW - nanogel-drug conjugate

UR - http://www.scopus.com/inward/record.url?scp=84906898076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906898076&partnerID=8YFLogxK

U2 - 10.1021/mp500290f

DO - 10.1021/mp500290f

M3 - Article

VL - 11

SP - 3112

EP - 3122

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 9

ER -